Talk:Small intestinal submucosa
From Wikipedia, the free encyclopedia
 |
This article is within the scope of the Molecular and Cellular Biology WikiProject. Please work to improve this article, or visit our project page to find other ways of helping. Thanks! |
||
| Stub | This article has been rated as stub-Class on the assessment scale. |
||
| Low | This article is on a subject of low-importance within molecular and cellular biology. | ||
|
Article Grading: The article has been rated for quality and/or importance but has no comments yet. If appropriate, please review the article and then leave comments here to identify the strengths and weaknesses of the article and what work it will need. |
|||
I think we need an article on small intestinal submucosa ... I'm far from an expert and pressed for time ... but at least want to get the term into the Wiki world. Keesiewonder 12:19, 12 November 2006 (UTC)
To get us started, here's a copy of a bit I contributed to an online conference for my current class:
I've ... seen references that small intestinal submucosa (SIS) (from pigs) has fared well as a non-immunogenic material. Kropp (1998) describes SIS as "an acellular, nonimmunogenic, biodegradable, xenogeneic, collagen-based material that is derived from the submucosa layer of porcine small intestine." For instance, one study showed that lining the inside of a pulmonary valved stent introduced endovascularly can prevent stent strut-related tissue damage (Stock et al., 2006). The endovascular procedure inherently involves a fair amount of disruption during the deployment method, so materials used need to be able to withstand the surgical procedure, in addition to being compatible with the patient's body.
Kropp, B. P. (1998). Small-intestinal submucosa for bladder augmentation: a review of preclinical studies. World Journal of Urology 16(4), 262-267. Abstract retrieved November 8, 2006 from [1]
Stock, U. A., Degenkolbe, I., Attmann, T., Schenke-Layland, K., Freitag, S., & Lutter, G. (2006). Prevention of device-related tissue damage during percutaneous deployment of tissue-engineered heart valves. Journal of Thoracic Cardiovascular Surgery 131,1323-1330. Abstract retrieved November 8, 2006 from [2]
Another article is [3]
As far as I can tell, SIS has been used in dozens of different therapeutic applications. Keesiewonder 19:39, 12 November 2006 (UTC)
